Madrigal Pharmaceuticals, Inc. MDGL Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Madrigal Pharmaceuticals, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Madrigal Pharmaceuticals, Inc.'s cash & equivalents?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported cash & equivalents of $232.19M in Q1 2026.
- How has Madrigal Pharmaceuticals, Inc.'s cash & equivalents changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s cash & equivalents increased by 23.1% year-over-year, from $188.65M to $232.19M.
- What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Madrigal Pharmaceuticals, Inc.'s cash & equivalents has grown at a 30.4% compound annual growth rate (CAGR), from $54M to $203.78M.
- What does cash & equivalents mean?
- The total amount of cash and highly liquid assets the company has available for immediate use.
- How do you interpret cash & equivalents?
- An increase suggests improved liquidity and a stronger buffer for R&D spending, while a decrease may indicate high cash burn rates or the need for future capital raises.
- How does cash & equivalents compare across companies?
- Peers in the clinical-stage biotech sector typically maintain high cash balances to fund multi-year clinical trials.